Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer

Tim A D Smith

Research output: Contribution to journalArticle

7 Citations (Scopus)
3 Downloads (Pure)

Abstract

Both mutant p53 and chemoresistance are poor prognostic factors in cancer. Many studies have examined the influence of these factors on fluoro-2-deoxy-D-glucose (FDG) incorporation. Whilst mutant p53 is associated with increased FDG incorporation, chemoresistance, especially when associated with P-glycoprotein, is associated with decreased FDG incorporation.
Original languageEnglish
Pages (from-to)51-55
Number of pages5
JournalNuclear Medicine and Biology
Volume37
Issue number1
Early online date27 Aug 2009
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Deoxyglucose
Neoplasms
P-Glycoprotein

Keywords

  • radionuclide study
  • treatment
  • cancer
  • 2-deoxy-2-fluoroglucose
  • chemotherapy
  • antineoplastic agent
  • mutation
  • p53 protein
  • prognosis
  • predictive factor
  • human
  • incorporation
  • treatment resistance
  • positron emission tomography
  • emission tomography
  • malignant tumor

Cite this

Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer. / Smith, Tim A D.

In: Nuclear Medicine and Biology, Vol. 37, No. 1, 01.2010, p. 51-55.

Research output: Contribution to journalArticle

@article{cf2b76fee770417fbff786fbc2ad6dab,
title = "Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer",
abstract = "Both mutant p53 and chemoresistance are poor prognostic factors in cancer. Many studies have examined the influence of these factors on fluoro-2-deoxy-D-glucose (FDG) incorporation. Whilst mutant p53 is associated with increased FDG incorporation, chemoresistance, especially when associated with P-glycoprotein, is associated with decreased FDG incorporation.",
keywords = "radionuclide study, treatment, cancer, 2-deoxy-2-fluoroglucose, chemotherapy, antineoplastic agent, mutation, p53 protein, prognosis, predictive factor, human, incorporation, treatment resistance, positron emission tomography, emission tomography, malignant tumor",
author = "Smith, {Tim A D}",
year = "2010",
month = "1",
doi = "10.1016/j.nucmedbio.2009.08.007",
language = "English",
volume = "37",
pages = "51--55",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer

AU - Smith, Tim A D

PY - 2010/1

Y1 - 2010/1

N2 - Both mutant p53 and chemoresistance are poor prognostic factors in cancer. Many studies have examined the influence of these factors on fluoro-2-deoxy-D-glucose (FDG) incorporation. Whilst mutant p53 is associated with increased FDG incorporation, chemoresistance, especially when associated with P-glycoprotein, is associated with decreased FDG incorporation.

AB - Both mutant p53 and chemoresistance are poor prognostic factors in cancer. Many studies have examined the influence of these factors on fluoro-2-deoxy-D-glucose (FDG) incorporation. Whilst mutant p53 is associated with increased FDG incorporation, chemoresistance, especially when associated with P-glycoprotein, is associated with decreased FDG incorporation.

KW - radionuclide study

KW - treatment

KW - cancer

KW - 2-deoxy-2-fluoroglucose

KW - chemotherapy

KW - antineoplastic agent

KW - mutation

KW - p53 protein

KW - prognosis

KW - predictive factor

KW - human

KW - incorporation

KW - treatment resistance

KW - positron emission tomography

KW - emission tomography

KW - malignant tumor

U2 - 10.1016/j.nucmedbio.2009.08.007

DO - 10.1016/j.nucmedbio.2009.08.007

M3 - Article

VL - 37

SP - 51

EP - 55

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 1

ER -